$15.00

+1.12 (+8.07%)

Weekly Expected Move ±8.8%

$11 $13 $14 $15 $16

NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 31 · $633.6M mcap · 28M float · 1.57% daily turnover · Short 44% of daily vol

Credit Risk of going bust: not rated Debt: 0.7% of company value Bonds: none of note held by US funds details ▾

Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$1.4B +2.6% ▲

5Y CAGR: -3.8%

Gross Profit

$1.4B +1.1% ▲

5Y CAGR: -4.3%

Operating Income

$72M +29.5% ▲

5Y CAGR: -9.0%

Net Income

-$90M -92.7% ▼

EPS (Diluted)

$-6.41 -93.1% ▼

EBITDA

$233M +16.3% ▲

5Y CAGR: +1.0%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2017	FY2018	FY2019	FY2020	FY2021
Revenue	$1.9B	$1.8B	$1.7B	$1.4B	$1.4B
YoY Growth	+9.3%	-5.4%	-6.1%	-17.3%	+2.6%
Cost of Revenue	$75M	$71M	$66M	$72M	$94M
Gross Profit	$1.8B	$1.7B	$1.6B	$1.3B	$1.4B
Gross Margin	96.1%	96.1%	96.1%	94.9%	93.5%
R&D Expenses	$0	$0	$0	$0	$0
SG&A Expenses	$1.4B	$1.4B	$1.3B	$1.1B	$1.1B
Operating Expenses	$1.8B	$1.7B	$1.6B	$1.3B	$1.3B
Operating Income	$92M	$90M	$64M	$56M	$72M
Operating Margin	4.8%	4.9%	3.7%	4.0%	5.0%
Interest Expense	$78M	$46M	$68M	$70M	$92M
Income Before Tax	-$1M	$34M	-$44M	-$42M	-$84M
Tax Expense	$12M	$13M	$36M	$5M	$6M
Net Income	-$17M	$18M	-$81M	-$47M	-$90M
Net Margin	-0.9%	1.0%	-4.7%	-3.3%	-6.2%
EPS (Diluted)	$-1.14	$1.24	$-5.59	$-3.32	$-6.41
EBITDA	$205M	$204M	$204M	$177M	$233M
Shares Outstanding	15M	15M	14M	14M	14M

Line Item	FY2021 Q2	FY2021 Q3	FY2021 Q4	FY2022 Q1	FY2022 Q2	FY2022 Q3	FY2026 Q1	FY2026 Q2
Revenue	$383M	$369M	$327M	$357M	$364M	$347M	$0	$450K
Cost of Revenue	$29M	$22M	$22M	$27M	$30M	$35M	$242K	$246K
Gross Profit	$354M	$347M	$305M	$329M	$334M	$311M	-$242K	$204K
Gross Margin	92.5%	94.0%	93.3%	92.3%	91.7%	89.8%	—	45.3%
R&D Expenses	$0	$0	$0	$0	$0	$0	$17M	$19M
SG&A Expenses	$290M	$272M	$274M	$279M	$284M	$256M	$3M	$3M
Operating Expenses	$332M	$326M	$340M	$324M	$337M	$304M	$20M	$22M
Operating Income	$22M	$20M	-$365M	$5M	-$132K	$14M	-$20M	-$22M
Operating Margin	5.8%	5.5%	-111.7%	1.3%	-0.0%	3.9%	—	-4845.1%
Interest Expense	$22M	$18M	$27M	$18M	$20M	$13M	$0	$0
Income Before Tax	-$6M	-$5M	-$55M	-$75M	-$16M	$15M	-$19M	-$21M
Tax Expense	$9M	$7M	-$11M	-$4M	-$4M	$14M	$0	$0
Net Income	-$15M	-$12M	-$44M	-$71M	-$12M	$1M	-$19M	-$21M
Net Margin	-3.9%	-3.2%	-13.4%	-19.8%	-3.3%	0.4%	—	-4597.1%
EPS (Diluted)	$-1.05	$-0.83	$-3.09	$-4.99	$-0.83	$0.10	$-0.48	$-0.45
EBITDA	$61M	$60M	-$290M	-$25M	$31M	$59M	-$20M	-$22M
Shares Outstanding	14M	14M	14M	14M	15M	15M	39M	46M

ATTO NASDAQ